Filed in archive
Corporate and Industrial News
, Drugs, Vaccines and Therapeutics
, Genomics, Proteomics and Bioinformatics
by ruth on January 23, 2007

"Our core competences lie within therapeutic proteins, and it is within this area that we can make the greatest difference in terms of patient outcomes and company growth. Therefore, it is a logical move to focus all our research and development efforts on this area."
All existing projects on small molecules, including NN9101, a glucokinase activator currently in phase 1 clinical testing, may be out-licensed.
Source: Novo Nordisk
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/50538
Mr Wong
Vote for Novo Nordisk Discontinues R&D on Small Molecules for Oral Treatment of Diabetes:
|
Rating: 5.33 out of 3 vote(s) cast.
|
Response from:
catrosinfo
(10/01/09 6:05am)
Thanks for sharing this post.
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |







